Endo Ketoprofen Patch Fails Two Phase III Studies; Firm Revises 2007 Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo awaits results from another Phase III efficacy study expected by Aug. 1 before it makes a go/no go decision on the product.
You may also be interested in...
Alpharma Ups Ante With Phase III Embeda Proof
Pain drug’s data could help lure more than King to the table.
Alpharma Ups Ante With Phase III Embeda Proof
Pain drug’s data could help lure more than King to the table.
Endo Financials Strong, But Shareholder Calls For Sale Of Company
CEO stepping down and no R&D leader on board, as officials evaluate pipeline.